Retatrutide is still in Phase 3 clinical trials and hasn't been FDA-approved. Because it's not approved, it can't be legitimately dispensed by a licensed pharmacy — including through 503A compounding. Platforms currently offering it are sourcing gray-market API from unregulated suppliers, which isn't a standard we compromise on. Once it's approved (Lilly is expected to file for approval in 2026), we'll evaluate adding it.
Why don’t you offer Reta?
Why Retatrutide is not on our product list.